Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations

BACKGROUND: Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib, gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced non-small-cell lung cancer (NSCLC) who harbor EGFR mutations. However, no head to head trials between these TKIs in mu...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Liang, Wenhua, Wu, Xuan, Fang, Wenfeng, Zhao, Yuanyuan, Yang, Yunpeng, Hu, Zhihuang, Xue, Cong, Zhang, Jing, Zhang, Jianwei, Ma, Yuxiang, Zhou, Ting, Yan, Yue, Hou, Xue, Qin, Tao, Dinglin, Xiaoxiao, Tian, Ying, Huang, Peiyu, Huang, Yan, Zhao, Hongyun, Zhang, Li
פורמט: Artigo
שפה:Inglês
יצא לאור: Public Library of Science 2014
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3922700/
https://ncbi.nlm.nih.gov/pubmed/24533047
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0085245
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים